(CercleFinance.com) – Bayer reports that recent data from a phase III trial has confirmed the consistent overall survival (OS) benefits of darolutamide combined with androgen deprivation therapy (ADT) and of docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC), compared to a current standard treatment, ADT + docetaxel.
A consistent benefit in overall survival was observed in different subgroups with darolutamide plus ADT and docetaxel compared to ADT plus docetaxel, with a reduction in the risk of death of 33% for the M1b subgroup and 21 % for M1c.
“These data underscore the potential of darolutamide as the optimal hormone therapy for eligible prostate cancer patients worldwide,” said Tara Frenkl, Head of Oncology Development at Bayer.
As a reminder, darolutamide is jointly developed by Bayer and Orion Corporation, a Finnish pharmaceutical company operating on a global scale.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
